Interplay Bio

Interplay Bio is an early-stage biotech leveraging its LigandPro platform to pioneer Targeted Protein Degradation (TPD) drug discovery. The company's core technology identifies small molecule ligands that bind to diverse protein surfaces, including non-traditional pockets, to enable the degradation of challenging targets. With a pipeline of early-stage candidates and a focus on collaboration, Interplay Bio is positioning itself to address high-need therapeutic areas like oncology and neurodegenerative diseases. The company is currently pre-revenue and seeking partnerships to advance its programs.

LigandPro platform for Targeted Protein Degradation (TPD) drug discovery. It identifies small-molecule ligands binding to any protein surface, maps poly-pharmacology, and discovers novel E3 ligase binders and molecular glues through a hypothesis-free screening approach.

Interplay Bio competes in the crowded Targeted Protein Degradation platform space with public companies like Arvinas, Kymera Therapeutics, Nurix Therapeutics, C4 Therapeutics, and Monte Rosa Therapeutics, as well as numerous private biotechs and internal large pharma efforts. Differentiation requires demonstrating superior ligand discovery capabilities, particularly for novel E3 ligases.